Efficient silencing of gene expression by an ASON-bulge-DNAzyme complex

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Yi, Jianzhong ^a   Liu, Chengqian ^a  

^a INSTITUTE OF EDIBLE FUNGI   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBOZYME; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; EFFECT SIZE; ENZYME SPECIFICITY; ENZYME SYNTHESIS; GENE CONSTRUCT; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; CONFORMATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

BASE SEQUENCE; DNA, CATALYTIC; GENE EXPRESSION; GENE SILENCING; GREEN FLUORESCENT PROTEINS; NUCLEIC ACID CONFORMATION;

EID: 79954481336     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018629     Document Type: Article

References (43)

1. Bronson SK, Smithies O, (1994) Altering mice by homologous recombination using embryonic stem cells. J Biol Chem 269: 27155-27158.
2. Paterson BM, Roberts BE, Kuff EL, (1977) Structural gene identification and making by DNA:mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 74: 4370-4374.
3. Mizuno T, Chou MY, Inouye M, (1984) A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA). Proc Natl Acad Sci USA 81: 1966-1970.
4. Izant JG, Weintraub H, (1984) Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis. Cell 36: 1007-1015.
5. Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstein F, (1991) Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 253: 314-317.
6. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
7. Kennerdell JR, Carthew RW, (1998) Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Cell 95: 1017-1026.
8. Zamecnik PC, Stephenson ML, (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Nat Acad Sci USA 75: 280-288.
9. Agrawal S, Zhao Q, (1998) Antisense therapeutics. Curr Opin Chem Biol 2: 519-528.
10. Galderisi U, Cascino A, Giordano A, (1990) Antisense oligonucleotides as therapeutic agents. J Cell Physiol 181: 251-257.
11. Gewirtz AM, (1998) Antisense oligonucleotide therapeutics for human leukemia. Curr Opin Hematol 5: 59-71.
12. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA, (1995) Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 270: 2620-2627.
13. Gao WY, Han FS, Storm C, (1992) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 41: 223-229.
14. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, et al. (1993) PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 365: 566-568.
15. Breaker RR, Joyce GF, (1994) A DNA enzyme that cleaves RNA. Chem Biol 1: 223-229.
16. Santoro SW, Joyce GF, (1997) A general purpose RNA cleaving DNAzyme. Proc Natl Acad Sci USA 94: 4262-4266.
17. Breaker RR, (2000) Making catalytic DNAs. Science 290: 2095-2096.
18. Sun L-Q, Cairns MJ, Saravolac EG, (2000) Catalytic nucleic acids: from lab to applications. Pharmacol Rev 52: 325-347.
19. Silverman SK, (2010) DNA as a versatile chemical component for catalysis, encoding, and stereocontrol. Angew Chem Int Ed Engl 49: 7180-7201.
20. Santoro SW, Joyce GF, (1998) Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 37: 13330-13342.
21. Kurreck J, Birgit B, Jahnel R, Erdmann VA, (2002) Comparative study of DNA enzyme and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J Biol Chem 277: 7099-7107.
22. Cairns MJ, Hopkins TM, Witherington C, Wang L, Sun L-Q, (1999) Target site selection for an RNA-cleaving catalytic DNA. Nat Biotechnol 17: 480-486.
23. Emilsson GM, Breaker RR, (2002) Deoxyribozymes New activities and new applications. Cellular and Molecular Life Sciences 59: 596-607.
24. Nielsen PE, Egholm M, Berg RH, Burchardt O, (1993) Peptide nucleic acids (PNAs): potential antisense and anti-gene agents. Anticancer Drug Res 8: 53-63.
25. Ota N, Warashina M, Hirano K, Hatanaka K, Taira K, (1998) Effects of helical structures formed by the binding arms of DNAzymes and their substrates on catalytic activity. Nucleic Acids Res 26: 3385-3391.
26. Castanotto D, Rossi JJ, (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-4.
27. Lares MR, Rossi JJ, Ouellet DL, (2010) RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28: 570-579.
28. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK, (2011) RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11: 59-67.
29. Perrimon N, Ni JQ, Perkins L, (2010) In vivo RNAi: today and tomorrow. Cold Spring Harb Perspect Biol 2: a003640.
30. Liu Q, Paroo Z, (2010) Biochemical principles of small RNA pathways. Annu Rev Biochem 79: 295-319.
31. Breaker RR, (2004) Natural and engineered nucleic acids as tools to explore biology. Nature 432: 838-845.
32. Chan SH, Stoddard BL, Xu SY, (2011) Natural and engineered nicking endonucleases-from cleavage mechanism to engineering of strand-specificity. Nucleic Acids Res 39: 1-18.
33. Franzen S, (2010) Expanding the catalytic repertoire of ribozymes and deoxyribozymes beyond RNA substrates. Curr Opin Mol Ther 12: 223-232.
34. Dass CR, Saravolac EG, Li Y, Sun L-Q, (2002) Cellular uptake, distribution and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev 12: 289-299.
35. Schubert S, Gul DC, Grunert HP, Zeichhardt H, Erdmann VA, et al. (2003) RNA cleaving ''10-23'' DNAzymes with enhanced stability and activity. Nucleic Acids Res 31: 5982-5992.
36. Werner M, Uhlenbeck OC, (1995) The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis. Nucleic Acids Res 23: 2092-2096.
37. Lam JC, Withers JB, Li Y, (2010) A complex RNA-cleaving DNAzyme that can efficiently cleave a pyrimidine-pyrimidine junction. Journal of molecular biology 23;400 (4): 689-701.
38. Wong JP, Christopher ME, Salazar AM, Sun LQ, Viswanathan S, et al. (2010) Broad-spectrum and virus-specific nucleic acid-based antivirals against influenza. Front Biosci (Schol Ed) 2: 791-800.
39. Schlosser K, Li Y, (2009) DNAzyme-mediated catalysis with only guanosine and cytidine nucleotides. Nucleic Acids Res 37 (2): 413-420.
40. Mastroyiannopoulos NP, Uney JB, Phylactou LA, (2010) The application of ribozymes and DNAzymes in muscle and brain. Molecules 15: 5460-5472.
41. Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK, (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41: 1023-1033.
42. Schubert S, Kurreck J, (2004) Ribozyme- and deoxyribozyme-strategies for medical applications. Curr Drug Targets 5: 667-81.
43. Tong-Hong Wang, Wan-Ting Li, Szu-Hsien Yu, Lo-Chun Au, (2008) The Use of 10-23 DNAzyme to Selectively Destroy the Allele of mRNA with a Unique Purine-Pyrimidine Dinucleotide. Oligonucleotides 18 (3): 295-300.